data sets required for their validation for non-volatile drugs, and the fact that such models are not readily ®tted to clinical pharmacokinetic data (although this has been done for pethidine in a detailed physiological model 8 ). Recirculatory pharmacokinetic models were developed over 20 yr ago, 9±11 but recently have emerged in anaesthesia as a middle ground between the two schools of pharmacokinetic modelling discussed above. 12±14 They retain the relative simplicity of mamillary models, but incorporate descriptions of key physiological processes that have emerged as important determinants of intravenous anaesthetic disposition. These include the role that cardiac output, lung kinetics, and injection rate play in dictating initial drug concentrations after i.v. bolus administration. Recent papers have shown that these factors can be incorporated into models of anaesthetic disposition and are consistent with data collected using instrumented sheep. 15 16 The hypothesis explored in this paper is that the contribution of cardiac output, lung kinetics, and injection rate can be explained by considering the arterial drug concentrations (C a ) to be the sum of two componentsÐthe ®rst-pass arterial concentrations (C a,f ) and the recirculated concentrations (C a,r ):
The ®rst-pass concentrations are affected by cardiac output, lung kinetics, and injection rate in a manner that has a direct analogy to indicator dilution methods used to measure cardiac output. 17 For bolus and short infusion administration, they can constitute most of the`total' arterial concentration (C a ), and thus the peak arterial concentration in many cases is also affected predominantly by cardiac output, lung kinetics, and injection rate.
It is proposed that knowledge of the concepts underlying recirculatory pharmacokinetics is best achieved by starting with the simplest recirculatory systemÐa two-compartment recirculatory model. The aim of this paper is to describe the structure and behaviour of this model while addressing the hypothesis outlined above. The equations of the model are provided for completenessÐthey are most useful if they are entered into a spreadsheet program so that the effect of cardiac output, lung kinetics, injection, rate and other factors on the time-course of drug concentrations (both total and ®rst-pass) can be examined graphically. The author proposes that this provides an introduction to a theoretical framework for drug disposition that matches the clinical experience of anaesthetists better than that provided by mamillary models.
Methods

Model structure
This paper will consider both the two-compartment recirculatory model ( Fig. 2A) , and a modi®ed form of the model that describes only the ®rst-pass concentrations (Fig. 2B) .
Recirculatory model
In comparison with a two-compartment mamillary model ( Fig. 1) , the two compartments of the recirculatory model ( Fig. 2A) are assigned physiological identitiesÐ the lungs and`rest of the body', respectively. Drug transport between the compartments (described by abstract rate constants in the mamillary model) are , and transfer of drug to the peripheral compartment is governed by rate constants k 12 and k 21 . R 0 and Cl are the drug infusion rate and clearance, respectively.
Fig 2 (A)
A two-compartment recirculatory model. In contrast to Figure  1 , the central compartment has been de®ned as the lungs, with the peripheral compartment as the remainder of the body (less the lungs). This necessitates de®ning two sites within the blood streamÐarterial and mixed venous. The rate constants have been replaced by the apparent distribution volumes of the compartments (V L and V B ) and a cardiac output (Q Ç CO ) term. Clearance has been renamed from Cl to Q Ç Cl in keeping with the fact that clearance also has the units of¯ow of blood. R 0 is the drug infusion rate. (B) The non-recirculating version of the model used to calculate the ®rst-pass concentrations.
replaced with rates of drug transport in real blood vessels. If, for convenience, the drug is infused into the pulmonary artery, there are two de®ning sites in the vasculature in the two-compartment recirculatory system: (1) mixed venous concentrations (C v ) upstream of the infusion and measured in blood returning from the body and (2) arterial concentrations (C a ) representing blood emerging from the lungs and entering the rest of the body. The rate of circulation of the blood between the two compartments is given by the cardiac output (Q Ç CO ). The apparent distribution volumes of the lung and body compartments are V L and V B , respectively, and drug clearance from the body compartment is given by Q Ç Cl . The apparent distribution volumes can be thought of as the amount of drug (mg) in each compartment normalized for (i.e. divided by) the arterial blood concentration (mg litre ±1 blood), which works out as litres of blood. This is the volume of blood that would contain the same amount of drug as the compartment if the two were in equilibrium (as at steady state). Similarly, drug clearance can be thought of as the rate of removal of the drug (mg min
±1
) from the body divided by the arterial blood concentration (mg litre ±1 blood), that is litres of blood per min (litre min ±1 ). This is the¯ow of blood at arterial concentration that, if it were completely cleared of drug, would account for the observed rate of removal.
The system of differential equations for the model (Fig. 2a) are derived by mass balance of the rates that drug enters and leaves the compartments:
Several issues should be pointed out. First, this model differs from that shown in Figure 1 in that elimination is from the`peripheral' rather than the central compartment. If this were not so, the equations for the recirculatory model could be obtained by substituting terms into the well-known equations for the standard two-compartment mamillary model. 18 Secondly, the equations describe an infusion at a rate given by`R 0 ' (e.g. mg min ±1 ). For bolus doses, this infusion can be treated more conveniently as dose (D, e.g. mg) given over a time interval equal to the duration of the injection (hereafter called the`injection time', t D ).
Thus, bolus doses cannot be speci®ed without also specifying the time over which the injection was madeÐthe implications of this will be discussed later. Thirdly, clearance cannot exceed cardiac outputÐthis is evident if clearance is thought of as a blood¯ow, as discussed previously.
First-pass model
The ®rst-pass model differs from the recirculatory model in only one respectÐmixed venous blood is not returned to the lungs (Fig. 2b) . The ®rst-pass arterial concentrations are therefore those resulting from drug molecules that have been infused into the pulmonary artery and have passed once through the lungs. The ®rst-pass venous concentrations are those resulting from drug molecules that have been infused and have passed once through the lungs and once through the body. The ®rst-pass concentrations occur in vivo, but are of course dif®cult to measure. The ®rst-pass arterial and mixed venous concentrations are designated C a,f and C v,f , respectively. In contrast, C a and C v from equation (2) will be called the`total' drug concentrations. These are the blood concentrations that can be measured directly via blood sampling from the appropriate blood vessels, and are the sum of the ®rst-pass (molecules that have made one circuit) and recirculated concentrations (molecules that have made more than one circuit) at any given time (equation (1)).
The differential equations for the ®rst-pass model are:
Note that this differs from equation (2a,b) only in that there is no term for C v in the right hand side of the upper equation. That is, mixed venous blood is not returned to the lungs.
Model equations
Steady state during a constant rate infusion At steady state, the rate of change of the concentrations (e.g. dC a /dt and dC v /dt) is zero. If this substitution is made into equations (2) and (4), then algebraic manipulation can be used to ®nd equations (5)±(10) in Table 1 , for the ®rst-pass and total concentrations at steady state. Dividing 5 by 8 shows that the ratio of the ®rst-pass arterial concentrations over the total concentrations at steady state is:
Complete equationsÐ®rst-pass model Solving equations (2) and (4) for the non-steady-state case is more dif®cult. The most common approach is to use Laplace transforms to convert the differential equations to polynomial equations, which can then be solved using matrix methods. This method was used here and has been well-described for other pharmacokinetic models, 19 and will not be repeated. Solving any two-compartment model resolves two hybrid rates constants (l 1 and l 2 ). 18 When the timecourse of the concentrations is plotted on a log-scale, these hybrid rate constants dictate the slopes of the two linear portions of the curve representing each exponential phase. For the ®rst-pass model, these are:
These hybrid rate constants can be expressed in other ways. Their inverse (1/l) gives the time constants (t) of each compartment. They can also be converted to half-lives (ln(2)/l).
The complete equations for the ®rst-pass model are given in Table 2 . The interplay of the parameter values is illustrated most simply in the exponential equation describing the time-course of the ®rst-pass arterial concentrations (Table 2, 13a) expressed for a bolus dose (see equation (3)) and with equation 12b substituted for l 1,f (equation (13b)).
Thus, the ®rst-pass arterial concentrations approach a steady-state value that is a function only of dose, injection time and cardiac output (equation (5) in Table 1 ). However, the rate at which they approach steady state (the exponential term) depends on cardiac output and the distribution volume of the lungs.
Complete equationsÐrecirculatory model
Adding recirculation to the model increases its complexity yet again. The exact hybrid rate constants for the recirculating system are: Table 1 Steady state. Equations describing the steady-state ®rst-pass and total drug concentrations during an infusion at a rate given by`R 0 '. The extraction ratio across the whole body (E B ) is 1 ± C v,f /C a,f , and 1 ± C v /C a for the ®rst-pass and total concentrations, respectively
Arterial concentration Table 2 The complete equations describing the models shown in Figure 2 . The values of the hybrid rate constants l 1,f , l 2,f , l 1 , and l 2 are calculated from equations (12) and (21) as given in the text. X 1 and X 2 are l 1 /Q Ç CO and l 2 /Q Ç CO , respectively. The values of
Mixed venous concentration
, and C v (t D ) are the respective last intra-infusion concentrationsÐthat is, the values of equations (13), (15), (17) , and (19) evaluated at time t=t D
During infusion Post-infusion
Arterial, ®rst-pass
Venous, ®rst-pass
Where:
For most biologically plausible parameter values, these complex equations can be approximated (T10%) with:
Thus, l 1 is dependent mainly on cardiac output, while l 2 is dependent mainly on clearance. The equations for the timecourse of the total arterial and venous concentrations (17± 20, Table 2 ) utilize these hybrid rate constants (21a,b). These are relatively complex, but with care can be entered into a spreadsheet program (the author can supply an example spreadsheet on request). Once in a spreadsheet, the time-courses of both the ®rst-pass and total concentrations in arterial and mixed venous blood can be calculated and plotted for any values of dose, injection time, cardiac output, clearance, and distribution volumes in the lungs and body. By way of example, these calculations were done for a hypothetical high-clearance induction agent under a variety of circumstances: with different cardiac outputs, different injection times for a ®xed bolus dose, and a rhythmicallȳ uctuating cardiac output during and after an infusion.
Fitting to data
While the main purpose in describing this model (Fig. 2a) is to illustrate recirculatory concepts, as for the two-compartment mamillary model (Fig. 1 ), the recirculatory model can be ®tted to concentration time-courses that show two exponential phases. However, the recirculatory model will only return meaningful parameter estimates when it is known that the fastest exponential is associated with lung kinetics (i.e. there are many early blood samples) and that lung kinetics can be adequately represented by a single compartment. A previously published data set 20 reporting the arterial thiopental concentrations in sheep (500 mg over 2 min) meets these criteria 21 Ðboth types of model were ®tted to these data for comparison. The software used was`Scientist for Windows 2.01' (Micromath, Salt Lake City, UT).
Results
Examples Steady state
The default parameter values of the hypothetical highclearance induction agent were: Q Ç CO =5 litre min ±1 , Q Ç Cl =2 litre min ±1 , V L =2.5 litre, and V B =15 litre. The steady-state total arterial concentration for this drug infused at 20 mg min ±1 was therefore 10 mg litre ±1 , as given by the classical formula R 0 /Q Ç Cl (equation (8)). The steady-state total mixed venous concentration (equation (9)) was lowerÐ6 mg litre ±1 ; the difference is because of clearance depleting drug in the venous blood returning from the body. For many hepatically cleared drugs, this is usually a result of the hepatic venous blood (which would be almost devoid of drug) mixing with non-depleted blood returning from other parts of the body. The whole body extraction ratio is the weighted average of this process once all the cardiac output has been mixed together, and is given by Q Ç Cl /Q Ç CO (equation (10)); in this example 2/5=0.4. Thus, the two-compartment recirculatory model introduces the concept of heterogeneity in the blood concentrations of a drug depending on whether blood at a particular site has been enriched by an upstream infusion (arterial in the present model), or depleted by an upstream organ of drug clearance (venous in the present model).
The steady-state ®rst-pass arterial concentration is given by equation (5) (R 0 /Q Ç CO ); in this example 20/5=4 mg litre ±1 . The ratio of C a,f /C a at steady state (equation (11)) is Q Ç Cl / Q Ç CO or 2/5=0.4. As Q Ç Cl must be less than or equal to Q Ç CO , it is apparent that the ®rst-pass concentration will always be less than or equal to the total concentration. In other words, the higher the clearance, the less the mixed venous concentration contributes to the total concentration.
Non-steady state
The ®rst-pass hybrid rate constants for the hypothetical drug were 2.0 and 0.33 min ±1 for the lung and body, respectively (at a cardiac output of 5 litre min ±1 ), equating to time constants of 0.5 and 3 min, and half-lives of 0.35 and 2.1 min, respectively. Note the hypothetical drug passes rapidly through the lungsÐthis is representative of both thiopental and propofol; respective half-lives of 0.30 and 0.52 min have been reported for these drugs in the lungs of sheep 21 . Such rapid equilibration of a drug in the lungs also means that the ®rst-pass arterial concentrations approach steady state very quickly during an infusion (equation (13a)), and that they are gone soon after the infusion ends.
The total hybrid rate constants for the hypothetical drug were 2.2 and 0.12 min ±1 for the lung and body, respectively (at a cardiac output of 5 litre min ±1 ), equating to time constants (t) of 0.45 and 8.3 min, and half-lives of 0.31 and 5.8 min, respectively. Figure 3 shows the time-course of both the ®rst-pass and total concentrations for the hypothetical drug for a dose rate of 20 mg min ±1 for 5 min. This shows the ®rst-pass arterial concentration rapidly approaching its steady-state value (4 mg litre ±1 ), while the peak total arterial concentration (approximately 6.5 mg litre ±1 ) was short of its steady-state value (10 mg litre ±1 ). Thus, the ®rst-pass concentrations made a signi®cant contribution to the total arterial concentrations during the short infusion. Note that the total venous concentrations also had a signi®cant component because of the ®rst-pass venous concentrations.
Sensitivity analysis
The effect of altering cardiac output for a short infusion is shown in Figure 4 . Increasing cardiac output decreased the Two-compartment recirculatory pharmacokinetic model peak total arterial concentration; this can be explained by the large contribution of the ®rst-pass arterial concentrations to the total concentration during and immediately after the bolus, and the signi®cant in¯uence of cardiac output on these ®rst-pass concentrations (equation (13a)). The lowest cardiac output was associated with delayed recirculation in that the mixed venous concentrations were lower and peaked later.
The effect of changing the injection time of a ®xed dose is shown in Figure 5 . Injection time had a profound effect on the peak arterial concentrations. Again, because of the relatively short injection time in all three cases there was little contribution from the venous return to the peak arterial concentration; in other words the ®rst-pass kinetics explain the arterial concentrations in the ®rst few minutes after the dose. By virtue of equations (3) and (5), the steady-state values of the ®rst-pass arterial concentration differed greatly with injection time (C a,f (ss) in Fig. 5 ). However, as the injection time was decreased, there was less time available for the ®rst-pass arterial concentrations to approach their steady-state value. The net effect was that decreasing the injection time caused higher peak ®rst-pass and total arterial concentrations (Fig. 5) . Note that for these parameter values, the difference between a 30 and 120 s injection was more profound than that between a 10 and 30 s injection.
The effect of acute variations in cardiac output (Fig. 6 ) clearly illustrates the contribution of the cardiac output dependent ®rst-pass concentrations to the total concentrations, even during a longer infusion. The ®rst-pass concentrations quickly settled at a value given by R 0 /Q Ç CO , as shown by equation (5) . However, as the cardiac output varied, so did the ®rst-pass concentration, albeit with a degree of damping' dictated by the distribution volume in the lung. As the recirculated concentrations were more heavily damped by the distribution volumes of the lungs and body, these varied less with cardiac output. During the infusion, the total concentrations (the sum of ®rst-pass and recirculated) therefore varied with cardiac output re¯ecting the contribution of the ®rst-pass component. However, very soon after the infusion, the ®rst-pass concentrations approached zero, leaving total concentrations much less affected by cardiac output and re¯ecting the contribution of the recirculated component.
Fitting to data
Both the mamillary and recirculatory models provided excellent ®ts of the data (Fig. 7) . The parameters of both models were also estimated with good precision (Table 3) . The estimated apparent volume of the lung (3.15 litres) was in broad agreement with the value measured by more direct means (2.49 litres) for a different data set in sheep. 21 
Discussion
This paper shows that a minor modi®cation of a twocompartment model can improve the representation of some of the fundamental physiological processes underlying drug disposition. It supports the hypothesis that, in some cases, there is merit in considering the drug concentration at any time to be the sum of ®rst-pass and recirculated components. For example, after bolus administration the in¯uence of cardiac output, lung kinetics, and injection time on the total drug concentration can be explained by the in¯uence of these factors on the underlying ®rst-pass concentrations. It is also evident that the simplest recirculatory model introduces the basic concepts important in recirculatory pharmacokinetics.
By incorporating recirculation into the two-compartment model, three biological principles are acknowledged. The qualitative behaviour of these principles are well understood by anaesthetistsÐtheir incorporation into a model de®nes their quantitative behaviour. The principles are: ®rst, that the blood recirculates at a rate given by the cardiac output. An i.v. drug is therefore added to a compartment through which blood is¯owing at a de®ned rate (the cardiac output) rather than directly into a`pool' of blood (the central compartment). The study of the addition of a drug or indicator to a¯ow is well developed, and when applied to the measurement of blood¯ow is broadly called indicator dilution principles. 17 Secondly, the lung is in the unique position of receiving all of the cardiac output, and all i.v. (and p.o., i.m., or s.c.) administered drugs must therefore pass through the lungs before entering the systemic circulation. The kinetics of drugs in the lung can therefore play a large part in modifying the initial concentrations of a drug. Thirdly, once the lungs are speci®ed, the heterogeneity of blood entering and leaving the lungs and the remainder of the body must be acknowledged. 
First-pass concentrations are governed by indicator dilution principles
Indicator (or tracer) dilution principles are familiar to many anaesthetists. The simplest principle describes the constant rate of addition of an indicator to a¯ow in a nonrecirculating systemÐthis is the basis for some continuous cardiac output monitors. Knowing the rate of addition, thē ow can be deduced from the concentration down stream of the infusion. In the two-compartment recirculatory model, the ®rst-pass arterial concentrations at steady state are governed by this principle in reverse, in that the concentrations are affected by the¯ow (equation (5)). For example, for the hypothetical drug discussed previously, if the dose rate is 20 mg min ±1 and the cardiac output is 5 litre min ±1 , in 1 min 20 mg has been added to 5 litres of blood, giving a steady-state ®rst-pass arterial concentration of 4 mg litre ±1 . If the cardiac output is increased to 10 litre min ±1 , in 1 min 20 mg must be added to 10 litres of blood, giving a concentration of 2 mg litre ±1 . This behaviour means that the ®rst-pass arterial concentrations respond acutely to changes in cardiac output. This is evident in Figure 6 , which shows a parameter set for which the total arterial concentrations during an infusion varied in response to an oscillating cardiac output. The recirculatory model predicts that arterial concentrations have the potential to be affected by transient changes in cardiac output much more during an infusion than after it.
The analogy with indicator dilution principles can be extended to bolus administration. Bolus administration of an indicator is used in the classical dye or thermodilution methods to measure cardiac output. The resultant indicator dilution curve can be used to estimate cardiac output from dose over AUC, where AUC is the area under the indicator curve with the effects of recirculation removed. The equations describing the ®rst-pass arterial concentrations (equations (13) and (14)) have a direct analogy to this principle, except that they are again applied`in reverse'. They produce a curve for which the AUC is a function of dose over cardiac output (D/Q Ç CO ). It is interesting to note that by ®tting the recirculatory model to the thiopental data, it was possible to estimate a plausible value for cardiac output (Table 3, 4.5 litre min ±1 ) solely from drug concentration data. This was possible as early blood samples were taken (necessary to de®ne lung kinetics), and there was no loss of thiopental on passage through the lungs (con®rmed experimentally).
Similar reasoning can be used for the effect of injection time on the ®rst-pass arterial concentrations. Injecting the same dose over half the time will double the amount of drug added to each volume of blood per unit time, thereby doubling the steady state ®rst-pass arterial concentrations. In practice, the steady-state concentration is rarely reached for short infusions (Fig. 5) , but the underlying effect remains when lung distribution volume is relatively small.
Lung kinetics
The need to incorporate the lungs into a model is a natural consequence of incorporating recirculation. Their unique location in the circulation means they are the only organ that can in¯uence the ®rst-pass arterial concentrations after i.v. administration. (5)). The ratio of t D /t (where t is the time constant for the lungs) indicates how close the ®rst-pass arterial concentrations at the end of the injection are to their steadystate value. A value of 3 indicates approximately 95% equilibration.
Two-compartment recirculatory pharmacokinetic model
The study of the kinetics of drugs in the lungs is complicated by the diversity of terminology and experimental methods used. 16 It is known from dual indicator studies that the arterial concentration`peak' emerging from the lungs after`impulse' i.v. injection has a complex shape governed partly by the distribution of intravascular transit times across the lungs. 22 It is known from isolated perfused lung studies that drugs can sequester into the lungs, and that some drugs exhibit multi-exponential washout curves. 23 However, in some cases simpler models of the lungs are suf®cient to capture the essential properties of lung kinetics in vivo on clinically relevant time-scales. 21 24 25 Thus, representing the lungs as a small single compartment in the present model was adequate for the case for thiopental ( Fig. 7 and Table 3 ). However, it does not follow that because a pharmacokinetic data set shows a bi-exponential increase or decline in blood concentration that the most rapid half-life is a function of lung kinetics. Blood samples must be taken suf®ciently early and at frequent intervals to de®ne the initial uptake or elution by the lungs before recirculation has an appreciable effect. Clearly, more con®dence can be placed in the appropriateness of a recirculatory model if experimental data on lung kinetics are available.
Heterogeneity of blood concentrations
The concept of blood concentrations being heterogeneous is absent in mamillary models. While the two-compartment recirculatory model resolves into two important blood concentrations (arterial and mixed venous), in practice the blood concentration at any point in the vasculature is a complex mix of the relative contribution of blood from different eliminating and non-eliminating tissues and the site of drug administration. Failure to account for this heterogeneity may explain some of the disparity in kinetic data for drugs in the past, where the precise origin of the blood used for pharmacokinetic analysis is not documented. Importantly, recirculatory models provide the opportunity to curve-®t mixed venous blood concentrations for kinetic analysis without error.
Limitations
The two-compartment recirculatory model is clearly an oversimpli®cation of the in vivo situation, particularly with the representation of the remainder of the body as a single compartment. Indeed, the use of compartments in itself is a limitation. 9 26 This would be most apparent for very short injection times (e.g. 1 s) that are signi®cantly less than the transit time of blood through the lungs. In this case, a more sophisticated representation of the lungs is required that accounts for the distribution of intravascular transit times. 22 It is possible to add additional`body' compartments to a recirculatory model if necessary, but this requires assumptions (or measurements) about the distribution of cardiac output in the body. However, the use of a single compartment is adequate for illustrating the principles underlying recirculatory models. A dynamic component can be readily incorporated into a recirculatory model by adding a target organ (e.g. the brain) for which there is a de®ned target organ concentration±effect relationship. This has been done for thiopental and propofol, 21 and provides the recirculatory model with a more physiological analogue to the commonly An important organ that is not adequately represented by the two-compartment recirculatory model is the kidneys. Their high relative perfusion and large percentage of the cardiac output means that drugs with small renal distribution volumes will rapidly pass through the kidneys and recirculate more rapidly than the theory dictated by the two-compartment representation.
Finally, note that clearance was treated as independent of cardiac output in this model, but this may not be the case for drugs that are highly extracted across the liver and therefore have¯ow-limited clearance. As liver blood¯ow is often a ®xed fraction of cardiac output, the clearance of this group of drugs will also be cardiac output dependent. 27 This may exacerbate any cardiac output dependency in kinetics over that predicted by the present model. . Note that the ®rst-pass concentrations were acutely affected by changes in cardiac output, but these concentrations were essentially present only during the intrainfusion period. The recirculated concentrations were less affected by the cardiac output, but persisted into the post-infusion period. The total concentrations (®rst-pass+recirculated) were therefore variable during the infusion, but less so afterwards.
Fig 7
The lines of best ®t for both a two-compartment recirculatory model, and a two-compartment mamillary model for the same previously published data (symbols) on the thiopental concentrations in arterial blood (mean of ®ve sheep) during and after the infusion of 500 mg over 2 min. 20 Both models provided excellent ®ts of the data (Table 3) . Table 3 Models ®tted to thiopental data. The best ®t values of the parameters of a two-compartment recirculatory model ( Fig. 2A) and a twocompartment mamillary model ( Fig. 1) ®tted (Fig. 7) to previously published data 20 on the mean arterial blood concentrations of thiopental during and after a 2 min infusion of 500 mg in ®ve sheep. The R 2 value of the ®t is also given 
Clinical implications
Despite its simplicity, the two-compartment recirculatory model provides a plausible explanation for a number of clinical phenomena. For example, it shows (Fig. 5 ) why slowing the rate of bolus injection of a ®xed dose of a drug can dramatically alter outcome. Depending on lung volume, signi®cantly lower peak arterial concentrations are achieved when a bolus is injected over 120 s rather than 10 s. Furthermore, the central role of cardiac output in the model (Fig. 4) may provide an explanation as to why the bolus dose of drugs required for low cardiac output (e.g. shock) patients is smaller than that for high cardiac output patients (e.g. sepsis, anxiety). Accounting for this cardiac output effect may improve the predictive power of clinical pharmacokinetic models across patient groups. The two-compartment recirculatory model is the simplest model that incorporates basic recirculatory concepts. These concepts may be more consistent with the clinical experience of many anaesthetists than those provided by its traditional mamillary counterpart. It is hoped that a wider knowledge of these concepts will facilitate research on the level of complexity of recirculatory models necessary to describe and predict clinical pharmacokinetic data.
